HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) All Versions of this Article: ard.2007.074104v1 67/4/478    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Miceli-Richard, C Articles by Mariette, X Search for Related Content PubMed PubMed Citation Articles by Miceli-Richard, C Articles by Mariette, X

A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis

¹ Rhumatologie, Institut Pour la Santé et la Recherche Médicale (INSERM) U 802, Université Paris-Sud 11, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Le Kremlin Bicêtre, France
² INSERM U 738, Paris, France; Université Paris 7, Paris, France
³ Pharmacologie, Centre d’Investigation Biologique (CIB), Hôpital Bicêtre, AP-HP, Le Kremlin Bicêtre, France
⁴ INSERM U 396, Immunologie et Histocompatibilité, Hôpital Saint-Louis, AP-HP, Paris, France
⁵ Département d’Epidémiologie, Biostatistique et Recherche Clinique, Hôpital Bichat, AP-HP, Paris, France
⁶ Abbott GmbH & Co. KG, Ludwigshafen, Germany

Correspondence to:
Pr Xavier MARIETTE, Service de Rhumatologie, Hôpital de Bicêtre, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre; xavier.mariette{at}bct.ap-hop-paris.fr

Objective: To determine whether tumour necrosis factor (TNF) gene polymorphisms and/or the shared epitope are genetic predictors of the response to adalimumab (ADA) in rheumatoid arthritis (RA).

Methods: This ancillary study to the Research in Active Rheumatoid Arthritis (ReAct) Phase IIIb study included a large cohort of Caucasian patients with RA from France (n = 388) treated with ADA plus methotrexate (MTX) (n = 182), ADA plus any other DMARD (n = 98) or ADA alone (n = 108). The primary outcome was ACR50 at 12 weeks. Patients underwent genotyping for HLA-DRB1 and three TNF gene polymorphisms (–238A/G,–308A/G and–857C/T). Extended haplotypes involving HLA-DRB1 and TNF loci were reconstructed using the PHASE program.

Results: A total of 151 patients (40%) had an ACR50 response at week 12. Neither the number of HLA-DRB1 shared epitope copies nor presence of the three TNF polymorphisms tested separately was significantly associated with ACR50 response at week 12. However, haplotype reconstruction of the TNF locus revealed that the GGC haplotype (–238G/–308G/–857C) in a homozygous form (i.e. present in more than half of the patients) was significantly associated with a lower ACR50 response to ADA at 12 weeks (34% vs. 50% in patients without the haplotype) (p = 0.003; pa = 0.015). This effect was more important in the subgroup of patients concomitantly treated with MTX.

Conclusion: This large pharmacogenetic study provides preliminary data indicating that a single TNF locus haplotype (–238G/–308G/–857C), present on both chromosomes is associated with a lower response to ADA, mainly in patients treated with ADA and MTX.